<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01885559</url>
  </required_header>
  <id_info>
    <org_study_id>DK62401-PKD-TN (IND)</org_study_id>
    <nct_id>NCT01885559</nct_id>
  </id_info>
  <brief_title>HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B</brief_title>
  <acronym>HALT-PKD</acronym>
  <official_title>Polycystic Kidney Disease-Treatment Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polycystic Kidney Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Federal Government</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the
      progression of cystic disease and on the decline in renal function in autosomal dominant
      kidney disease (ADPKD) will be assessed in two simultaneous multicenter randomized clinical
      trials targeting different levels of kidney function: 1) early disease defined by GFR &gt;60
      mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60
      mL/min/1.73 m2 (Study B). Participants will be recruited and enrolled, either to Study A or
      B, over the first three years. Participants enrolled in Study B will be followed for
      five-to-eight years, with the average length of follow-up being six and a half years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      * Specific Aim of Study B

      To study the effects of ACE-I/ARB combination therapy as compared to ACE-I monotherapy in
      the setting of standard blood pressure control (110-130/80 mm Hg) on the time to a 50%
      reduction of baseline eGFR, ESRD or death, in hypertensive individuals with moderate renal
      insufficiency (GFR 25-60 mL/min/1.73m2).

      * Hypothesis to be tested in Study B

      In hypertensive ADPKD individuals with moderate renal insufficiency (GFR 25-60 mL/min/1.73
      m2), intensive blockade of the RAAS using combination ACE-I/ARB therapy will slow the
      decline in kidney function over ACE-I monotherapy, independent of standard blood pressure
      control (110-130/80 mm Hg).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to 50% reduction of baseline eGFR, ESRD (initiation of dialysis or preemptive transplant), or death.</measure>
    <time_frame>Patients followed for 5-8 years with average of 6.5 years follow up</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>up at 8 years (annually assessed)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>up to 8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Hospitalizations</measure>
    <time_frame>up to 8 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Physical Component</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Mental Component Summary</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">486</enrollment>
  <condition>Kidney, Polycystic</condition>
  <arm_group>
    <arm_group_label>ACE-I + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-I + ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril and Placebo</intervention_name>
    <description>Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
    <arm_group_label>ACE-I + placebo</arm_group_label>
    <other_name>ACE-I</other_name>
    <other_name>ACE</other_name>
    <other_name>Ace-Inhibitor</other_name>
    <other_name>Lisinopril</other_name>
    <other_name>ARB</other_name>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril and Telmisartan</intervention_name>
    <description>Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
    <arm_group_label>ACE-I + ARB</arm_group_label>
    <other_name>ACE-I</other_name>
    <other_name>ACE</other_name>
    <other_name>Ace-Inhibitor</other_name>
    <other_name>Lisinopril</other_name>
    <other_name>ARB</other_name>
    <other_name>Telmisartan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ADPKD.

          -  Age 15-49 (Study A); Age 18-64 (Study B).

          -  GFR &gt;60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).

          -  BP ≥130/80 or receiving treatment for hypertension.

          -  Informed Consent.

        Exclusion Criteria:

          -  Pregnant/intention to become pregnant in 4-6 yrs.

          -  Documented renal vascular disease.

          -  Spot urine albumin-to-creatinine ratio of &gt;0.5 (Study A) or ≥1.0 (Study B) and/or
             findings suggestive of kidney disease other than ADPKD.

          -  Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of
             &gt;126 mg/dl / random non-fasting glucose of &gt;200 mg/dl.

          -  Serum potassium &gt;5.5 mEq/L for participants currently on ACE-I or ARB; &gt;5.0 mEq/L for
             participants not currently on ACE-I or ARB.

          -  History of angioneurotic edema or other absolute contraindication for ACE-I or ARB.
             Intolerable cough associated with ACE-I is defined as a cough developing within six
             months of initiation of ACE-I in the absence of other causes and resolving upon
             discontinuation of the ACE-I.

          -  Indication (other than hypertension) for β-blocker or calcium channel blocker therapy
             (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site
             principal investigator. (PI may choose to accept an individual who is on only a small
             dose of one of these agents and would otherwise be eligible.)

          -  Systemic illness necessitating NSAIDs, immunosuppressant or immunomodulatory
             medications.

          -  Systemic illness with renal involvement.

          -  Hospitalized for acute illness in past 2 months.

          -  Life expectancy &lt;2 years.

          -  History of non-compliance.

          -  Unclipped cerebral aneurysm &gt;7mm diameter.

          -  Creatine supplements within 3 months of screening visit.

          -  Congenital absence of a kidney (also total nephrectomy for Study B).

          -  Known allergy to sorbitol or sodium polystyrene sulfonate.

          -  Exclusions specific to MR imaging (Study A).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Schrier, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arlene Chapman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Perrone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University-New England Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Torres, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marva Moxey-Mims, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charity G Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver (Aurora)</city>
        <state>Colorado</state>
        <zip>800045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pkd.wustl.edu/pkdtn</url>
    <description>HALT PKD Home Page</description>
  </link>
  <link>
    <url>http://www.pkdcure.org</url>
    <description>Polycystic Kidney Disease Foundation Website</description>
  </link>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 20, 2013</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>polycystic kidney disease</keyword>
  <keyword>polycystic</keyword>
  <keyword>kidney</keyword>
  <keyword>disease</keyword>
  <keyword>adpkd</keyword>
  <keyword>halt</keyword>
  <keyword>pkd</keyword>
  <keyword>blood pressure</keyword>
  <keyword>bp</keyword>
  <keyword>hypertension</keyword>
  <keyword>renal</keyword>
  <keyword>renin-angiotensin-aldosterone-system</keyword>
  <keyword>RAAS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
